Astec LifeSciences Limited reported consolidated total income of Rs. 91.6 crore in Q1 FY26 as compared to Rs. 70.3 crore in Q1 FY25, an increase of 30.3%.

The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year.

Commenting on the performance, N. B. Godrej, Chairman, Astec LifeSciences Limited said, "Astec reported improvement in performance on a year on year basis on the back of improvement in volumes & contribution in its enterprise business. Revenue in enterprise & CDMO businesses increased year on year by 68.2% & 85.7% respectively. This also resulted in reduction of EBITDA losses as compared to Q1 FY25, which also had an impact of write down of Inventories of Rs. 18.5 crore."